New financial products should be subjected to the kind of rigorous testing that pharmaceuticals undergo, while financial services companies should be required to run drills with employees that simulate credit crunch-type crises.
New financial products should be subjected to the kind of rigorous testing that pharmaceuticals undergo, while financial services companies should be required to run drills with employees that simulate credit crunch-type crises.